Trial Profile

GU-187: Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
Indications Neuroendocrine tumours; Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

19 Sep 2024 An additional Cohort C (n=25) is added and patients with Neuroendocrine Tumors will be also enrolled in Cohorts A and C.
19 Sep 2024 Planned number of patients changed from 86 to 111.
08 Mar 2024 Number of treatment arms have been increased from 1 to 2 by the addition of Cohort B Experimental: Cabozantinib and nivolumab arm, and the study design is changed from single group to parallel. Treatment naive patients will now be included in cohort B, for which an additional primary efficacy end point is also added.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com